Navigation Links
ERT Awarded over $10 Million of ePRO Business from Major Pharma - Increasing its Position as a Leading ePRO Provider
Date:4/14/2011

PHILADELPHIA, April 14, 2011 /PRNewswire/ -- ERT (Nasdaq: ERT), a global technology-driven provider of clinical services and customizable medial devices to biopharmaceutical and healthcare organizations, announced today that it was awarded three new contracts with top tier pharmaceutical companies, totaling over $10 million for its electronic patient reported outcomes (ePRO) business. The company has been selected to provide its diverse multi-modality solutions, reinforcing its position as a leading provider of multi-mode ePRO devices and services.

ERT is the leading provider of cardiac safety and respiratory solutions and now demonstrates that it is gaining increasing market share in the ePRO market. ERT offers a broad range of ePRO solutions to collect accurate subject self-reports and real-time data during a clinical trial. The most significant ePRO award is an exclusive agreement with a specialty division of a top 5 pharmaceutical company that has selected ERT to manage a suite of studies using ERT's proprietary VIAPhone platform over the next three years.  The contract will be worth in excess of $7.0 million. The second award is part of a $3.0 million contract for which ERT will provide its VIAPen solution for a pivotal Phase III program. The third award has been secured with a top 10 pharmaceutical company who will be using ERT's unique VIAPhone Pain Diary for use in a Phase III clinical trial, alongside its VIAPen solution for site assessments, as part of a $1.2 million contract.

ERT now offers a diverse range of complementary ePRO tools accepted globally by regulatory authorities for the collection of reliable accurate data. These solutions include an IVR solution (VIAPhone®), a handheld device (VIAPad®), a digital pen (VIAPen®) and an internet application (VIAWeb®).  All offer the advantages of simplicity, mobility and immediacy of use over traditional paper-based methods. Based on its broad range of ePRO tools, ERT is the only company in the industry currently offering clients truly independent solutions and advice that allow customers to choose the most appropriate ePRO modality taking into consideration complexity, length, site location, patient population, budget and size of trial.

John Blakeley, Chief Commercial Officer at ERT, comments: "This significant amount of new business in one quarter reflects ERT's unique market position as a company that offers an integrated suite of products and services that can be customized to meet our clients' needs. The broad scope of our solutions and expertise ensures that we are able to offer clients unbiased, 'true partnership' advice that allows for an accurate and cost-effective trial. Sponsors are increasingly choosing ERT for our industry knowledge and expertise as well as secure and reliable service."

For further information on ERT and its technology and services, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, Email ert@scottpr.co.uk.

About ERTERT (www.ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.  It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic Patient Reported Outcomes (ePRO) in multiple modalities across all phases of clinical research.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.Media Contacts:Fiona Robinson

John BlakeleyThe Scott Partnership

ERT Tel: +44 1477 539539

+1 215 972 0420ert@scottpr.com

jblakeley@ert.com  
'/>"/>

SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
2. Dr. Yong Shi awarded NSF grant
3. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
4. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
5. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
6. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
7. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
8. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
9. Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
10. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
11. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... ... September 12, 2017 , ... September 15, 2017. Pittsburgh, ... Head of the Department of Surgery and Cancer and Director of the MRC-NIHR ... Lecture. His presentation, “Analytical Science in Precision Medicine: Facing the Challenges of ...
(Date:9/12/2017)... Budapest, Hungary & Cambridge (PRWEB) , ... September ... ... in Budapest with US offices in Cambridge, MA, announce today that Holotype HLA ... or collaborators at the annual meeting of the American Society for Histocompatibility ...
(Date:9/12/2017)... ... September 12, 2017 , ... ... accelerate pharmaceutical and biotherapeutics development, announces a new publication in Biosensors ... biosensor. Antibodies developed by the Centers for Disease Control (CDC) were used to ...
(Date:9/12/2017)... (PRWEB) , ... September 12, 2017 , ... ... lithography equipment for the semiconductor, MEMS, and microfluidics industries, announced today that multiple ... installed. OAI’s unique, modular design approach adds the flexibility required to meet the ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
Breaking Biology News(10 mins):